Working… Menu

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04708210
Recruitment Status : Recruiting
First Posted : January 13, 2021
Last Update Posted : May 7, 2021
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary:
An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and preliminary efficacy of IBI319 in patients with advanced malignant tumors

Condition or disease Intervention/treatment Phase
Advanced Malignant Tumors Drug: IBI319 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 256 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors
Actual Study Start Date : April 28, 2021
Estimated Primary Completion Date : May 21, 2024
Estimated Study Completion Date : August 21, 2024

Arm Intervention/treatment
Experimental: Phase Ia Dose-Escalation Stage: IBI319 Drug: IBI319
Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.

Primary Outcome Measures :
  1. Number of patients with DLT, AE, treatment-related AE (TRAE), immune-related AEs (irAE), AE of special interest (AESI), serious adverse event (SAE), discontinuation of study drug due to AE, dose-limiting toxicity (DLT) assessed by CTCAE v5.0 [ Time Frame: up to 2 years ]

Secondary Outcome Measures :
  1. Overall response rate (ORR) based on RECIST v1.1 criteria and Lugano 2014 criteria. [ Time Frame: up to 2 years ]
  2. Progression-free survival (PFS) based on RECIST v1.1 criteria and Lugano 2014 criteria [ Time Frame: up to 2 years ]
  3. Overall Survival (OS) based on RECIST v1.1 criteria and Lugano 2014 criteria [ Time Frame: up to 2 years ]
  4. Time To Response(TTR) based on RECIST v1.1 criteria and Lugano 2014 criteria [ Time Frame: up to 2 years ]
  5. Duration of Response(DOR) based on RECIST v1.1 criteria and Lugano 2014 criteria [ Time Frame: up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures.
  2. Patients with advanced solid tumors or hematological malignancies who had failed standard treatment.
  3. Male or female subjects ≥18 years and ≤75 years.
  4. At least one measurable lesion (per RECIST version 1.1) in solid tumor patients and at least one measurable and hyper metabolic in 18F-FDG lesion (per Lugano2014) in lymphoma patients
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.
  6. Subjects with life expectancy of ≥ 12 weeks.
  7. Subjects must have adequate organ function (liver, kidney function and hematopoietic function tests) prior IBI319 administration

    1. Absolute neutrophil count (ANC) ≥1.5 x10^9/L
    2. Platelet count ≥ 100 x 10^9/L
    3. Hemoglobin ≥ 9 g / dL (whole blood or component transfusion within 7 days before 1st dose of study drug is prohibited)
    4. Renal function tests: an estimated glomerular filtration rate (eGFR) ≥ 50 mL/min
    5. Liver function tests alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN, for patients with known liver cancer or liver metastases, AST and ALT ≤ 5 x ULN
    6. Total bilirubin (TBil) ≤1.5 x ULN; If Gilbert's Syndrome may have Bilirubin> 2 x ULN
    7. Coagulation tests: APTT ≤ 1.5 x ULN and INR ≤1.5 x ULN
  8. Subjects (males and females) of childbearing potential should be willing to use reliable contraception methods that are deemed effective by the investigator from visit 1 through 180 days following the last dose of study drug.

Exclusion Criteria:

  1. Legal incapacity or limited legal capacity.
  2. Pregnancy, lactation, breastfeeding.
  3. Prior treatment with an anti-CD137, anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2, anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or drug (except for Ib cohort A and B).
  4. NSCLC patients with EGFR mutations or ALK gene rearrangements.
  5. Colorectal cancer patients with KRAS mutation / BRAF mutation / HER2 overexpression.
  6. Concurrent anticancer treatment or use of other investigational product within 4 weeks before start of trial treatment; major surgery within 4 weeks before start of trial treatment (excluding prior diagnostic biopsy).
  7. Failure to recover from adverse events from the most recent anti-tumor treatment to CTCAE ≤ grade 1 or baseline with the exception of alopecia.
  8. Acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
  9. Subjects with CNS metastasis unless they are asymptomatic or adequately treated with radiotherapy and/or surgery and subjects are neurologically stable with minimal residual symptoms/signs.
  10. Any other serious underlying medical (e.g., uncontrolled hypertension, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, other serious cardiac conditions not listed in exclusion criteria), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04708210

Layout table for location contacts
Contact: Fen Yao 0512-69566088

Layout table for location information
Guangdong Provincial People's Hospital Recruiting
Guangdong, China
Contact: Yilong Wu    020-83821484   
Sponsors and Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
Layout table for investigator information
Principal Investigator: Yilong Wu Guangdong Provincial People's Hospital
Layout table for additonal information
Responsible Party: Innovent Biologics (Suzhou) Co. Ltd. Identifier: NCT04708210    
Other Study ID Numbers: CIBI319A101
First Posted: January 13, 2021    Key Record Dates
Last Update Posted: May 7, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms